Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Bondronat, Bonviva; Belgium: Bondronat, Bonviva; Bulgaria: Bonviva; Czech Republic: Bondenza, Bondronat, Bonviva; Denmark: Bondronat; Estonia: Bondenza, Bondronat, Bonviva; Finland: Bondronat, Bonviva; France: Bondronat, Bonviva; Germany: Bondenza, Bondronat, Bonviva; Greece: Destara; Hungary: Bondenza, Bondronat, Bonviva; Ireland: Bondenza, Bondronat, Bonviva, Ibandronic Acid; Italy: Bondronat, Bonviva; Latvia: Bondenza, Bondronat, Bonviva; Luxembourg: Bondenza, Bondronat, Bonviva; Malta: Ibandronic Acid; Netherlands: Bondenza, Bondronat, Bonviva, Destara; Poland: Bondenza, Bondronat, Bonviva; Portugal: Acido Ibandrónico, Bondenza, Bondronat, Bonviva; Spain: Bondenza, Bondronat, Bonviva; Sweden: Bondenza, Bondronat, Bonviva; UK: Bondronat, Bonviva.

North America

USA: Boniva.

Latin America

Argentina: Adromux, Bandrobon, Bantuc, Bonviva, Brexell Plus, Deltrox, Elasterin, Femorel, Ibanleg, Idena, Modifical-Beta, Silidral Uno; Brazil: Bonviva; Mexico: Bonviva.

Drug combinations


Ibandronate Sodium: C~9~H~22~NNaO~7~P~2~ H~2~O. Mw: 359.23. Sodium trihydrogen [1-hydroxy-3-(methylpentylamino)propylidene]diphosphonate, monohydrate. CAS-138926-19-9 (1997).

Pharmacologic Category

Bone Resorption Inhibitors; Bisphosphonate Derivative. (ATC-Code: M05BA06).

Mechanism of action

Incorporates into bone and selectively inhibits osteoclast-mediated bone resorption. Reduces biochemical markers of bone resorption in postmenopausal osteoporosis. Maintains or increases bone mineral density and increases bone mass in postmenopausal women.

Therapeutic use

Treatment and prevention of osteoporosis in postmenopausal women.

Pregnancy and lactiation implications

Safety and efficacy not established in pregnant women. Bisphosphonates are incorporated into bone matrix and gradually released over time. There may be risk of fetal harm when pregnancy follows completion of therapy.

Unlabeled use

Hypercalcemia of malignancy. Corticosteroid-induced osteoporosis. Paget’s disease. Reduction of bone pain and skeletal complications from metastatic bone disease.


Hypersensitivity to ibandronate, other bisphosphonates, or any component of the formulation. Hypocalcemia. Oral tablets also contraindicated in patients unable to stand or sit upright for at least 60 minutes.

Warnings and precautions

Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain reported during bisphosphonate treatment (avoid use in history of these symptoms in association with bisphosphonate therapy). Gastrointestinal mucosa irritation possible (use with caution in duodenitis, dysphagia, esophageal disease, gastritis, or ulcers). Osteonecrosis of jaw might occur (observed mostly in cancer patients, but also in postmenopausal osteoporosis and other diagnoses). Invasive dental procedures should be avoided during treatment. Before therapy initiation hypocalcemia must be corrected. Use not recommended with severe renal impairment (CrCl <30 mL/minute or serum creatinine >2.3 mg/dL). Intravenous bisphosphonates may cause transient decreases in serum calcium and also associated with renal toxicity.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart